April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Improvements in Macular Function in Neovascular Age-related Macular Degeneration patients Treated with Ranibizumab
Author Affiliations & Notes
  • Laura Milner
    Clinical Eye Research Unit,
    Royal Liverpool University Hospital, Liverpool, United Kingdom
  • Claudio Campa
    Clinical Eye Research Unit,
    Royal Liverpool University Hospital, Liverpool, United Kingdom
  • Richard P. Hagan
    Department of Medical Physics and Clinical Engineering,
    Royal Liverpool University Hospital, Liverpool, United Kingdom
  • Malcolm C. Brown
    Department of Medical Physics and Clinical Engineering,
    Royal Liverpool University Hospital, Liverpool, United Kingdom
  • Simon P. Harding
    Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom
  • Footnotes
    Commercial Relationships  Laura Milner, None; Claudio Campa, None; Richard P. Hagan, None; Malcolm C. Brown, None; Simon P. Harding, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1681. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Laura Milner, Claudio Campa, Richard P. Hagan, Malcolm C. Brown, Simon P. Harding; Improvements in Macular Function in Neovascular Age-related Macular Degeneration patients Treated with Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1681.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate macular function changes in patients with neovascular age-related macular degeneration (nAMD) undergoing ranibizumab treatment over a period of 12 months.

Methods: : Patients with nAMD were recruited into an observational longitudinal study and examined at baseline, 3, 6 and 12 months. The effect of ranibizumab anti-VEGF treatment upon macular function was assessed using multifocal electroretinography (mfERG)(Retiscan, Roland Consult) and microperimetry (MP1)(Nidek). These were compared to the standard outcome measure of refraction protocol best corrected visual acuity (BCVA) measured on ETDRS charts.

Results: : 14 patients were recruited. Mean mfERG P1 response amplitude from the central hexagon improved from the baseline value of 26.8 nV/deg2 to 47.5 nV/deg2 at 3 months, 42.6 nV/deg2 at 6 months and 38.6 nV/deg2 at 12 months (repeat-measure ANOVA, p=0.021). The mean P1 amplitudes from ring 2 and ring 3 of the mfERG did not change by a clinically significant amount over the 12 month period (ΔR2 < 4 nV/deg2 and ΔR3 < 2.5 nV/deg2). There was no significant change in mean hexagon response latency over the 12 months.Median visual acuity improved from 57.5 ETDRS letters at baseline to 69, 67 and 66 letters at 3, 6 and 12 months respectively (p=0.002). Mean retinal sensitivity inside the central 4degrees improved from 2.8 dB at baseline to 6.7 dB, 5.6 dB and 5.9 dB at 3, 6 and 12 months respectively (p=0.007).

Conclusions: : Central retinal function as measured by mfERG and MP1 significantly improved over a 12 month course of ranibizumab therapy and paralleled improvements in BCVA. Some subjects did not respond to treatment and further investigation into mechanisms of response is warranted. Measures of central function other than BCVA should prove useful in measuring treatment effects in future treatment trials.

Keywords: age-related macular degeneration • electroretinography: clinical • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×